Telomere Science still has a lot of work ahead of itself…there are many factors that contribute to the aging process…so if a test can predict when I will die…perhaps in the future we can manipulate the strands of our DNA to extend our lives to 120 years of age. It sounds like science fiction ….but remember many ideas have started out as an impossibility…only to develop into a feasible application to enhance the quality of life.
http://www.yepod.com/?p=14786
Pass it on,
Dr Anthony
This article titled “Can a blood test really tell you when you’ll die?” was written by Giles Tremlett, for The Guardian on Tuesday 11th October 2011 19.00 UTC
As a taxi takes me across Madrid to the laboratories of Spain’s National Cancer Research Centre, I am fretting about the future. I am one of the first people in the world to provide a blood sample for a new test, which has been variously described as a predictor of how long I will live, a waste of time or a handy indicator of how well (or badly) my body is ageing. Today I get the results.
Some newspapers, to the dismay of the scientists involved, have gleefully announced that the test – which measures the telomeres (the protective caps) on the ends of my chromosomes – can predict when I will die. Am I about to find out that, at least statistically, my days are numbered? And, if so, might new telomere research suggesting we can turn back the hands of the body’s clock and make ourselves “biologically younger” come to my rescue?
The test is based on the idea that biological ageing grinds at your telomeres. And, although time ticks by uniformly, our bodies age at different rates. Genes, environment and our own personal habits all play a part in that process. A peek at your telomeres is an indicator of how you are doing. Essentially, they tell you whether you have become biologically younger or older than other people born at around the same time.
The key measure, explains María Blasco, a 45-year-old molecular biologist, head of Spain’s cancer research centre and one of the world’s leading telomere researchers, is the number of short telomeres. Blasco, who is also one of the co-founders of the Life Length company which is offering the tests, says that short telomeres do not just provide evidence of ageing. They also cause it. Often compared to the plastic caps on a shoelace, there is a critical level at which the fraying becomes irreversible and triggers cell death. “Short telomeres are causal of disease because when they are below a [certain] length they are damaging for the cells. The stem cells of our tissues do not regenerate and then we have ageing of the tissues,” she explains. That, in a cellular nutshell, is how ageing works. Eventually, so many of our telomeres are short that some key part of our body may stop working.
The research is still in its early days but extreme stress, for example, has been linked to telomere shortening. I think back to a recent working day that took in three countries, three news stories, two international flights, a public lecture and very little sleep. Reasonable behaviour, perhaps, for someone in their 30s – but I am closer to my 50s. Do days like that shorten my expected, or real, life-span?
People with similar worries – or, perhaps, just Woody Allen-style neuroses about their health – have begun to contact the company set up by Blasco. Requests have poured in from around the world since a headline writer at the Independent, perhaps misled by Life Length‘s ambiguous name, invited readers to find out about “The £400 test that tells you how long you’ll live.” The internet did the rest.
Originally set up to help researchers and the pharmaceutical, health food and cosmetics industries test the impact of their products on telomeres, the flood of individual requests has caught Blasco’s still tiny company by surprise. But the test is available, as of this month, via doctors in Spain and Portugal and there are plans to make it easier to carry out in the UK and the US as soon as possible. It sees a potential gold-mine in testing of what it calls people’s “biological age” – though it is by no means alone in the field. So what can Blasco tell me about my test?
“You actually have very good news,” she says, pointing at a chart that looks as if it has been blasted by shotgun pellets. My telomeres – especially the more dangerous, shortest ones – are in better shape than would be normal for my age. The pellet points are individual results from those people who have been tested and introduced into this database so far, and the red dot representing my blood sample is on the better side of the two graphs Blasco shows me. One graph shows median telomere length, while the other shows how many crucially short telomere endings I have. In each case, a line on the graph shows the average result against age. The test on some 100,000 of my telomeres, compared with the other results on the admittedly small database being used by Life Length when this test was done in the summer, give me a “biological age” six years below my real age. With only 90 other men on the chart so far, all with different lifestyles and genetic backgrounds to mine, I should avoid feeling smug. Eventually, when there are thousands or more on the database, I might get a better idea of what results people more like me should expect. I have a reasonably healthy lifestyle, after all, and previous generations on both sides of my family have been long-lived.
However, according to a New York Times interview with 2009 Nobel prize-winner Carol Greider – who Blasco trained under – individual telomere tests are not much use. “The science really isn’t there to tell us what the consequences are of your telomere length,” she said.
Blasco, obviously, disagrees. So does Elizabeth Blackburn, who shared the Nobel prize for telomere research with Greider and Jack Szostak, and has set up her own Telome Health company to start offering tests later this year.
Blasco compares the current state of telomere testing to the early days of cholesterol tests – and believes it should become common once the price drops and research is done to beef up databases, improve interpretation and create telomere-restoring treatments. “This is a different kind of marker. It is a new, molecular marker. Even though we measure telomere length in blood cells, it has been shown to be an indicator of the degree of telomere shortening in the whole organism,” she says. “And we think it is very powerful, based on what we know from hard science.” Even so, she is insistent that the test is not a magic measure of individual life length. “We don’t tell anyone how long they will live.
“It is the doctor – and we want to do this with doctors – who will tell you what is known about the meaning of this measurement and what you can do and what you cannot do,” says Blasco. In fact, the benefits of telomere science still lie mostly in the future. As with early cholesterol tests, a doctor is currently unable to tell you much about what those results mean – or what you can do about a bad result, beyond fairly obvious advice about looking after your health.
I notice that a few of the 90 men on my chart have apparently alarming results. Their telomeres indicate a “biological age” 20 years or more higher than their real age. This means that, at least statistically, they may be much closer to death than most people their age. One of these men comes from a family with a long history of early cancers, according to Life Length’s CEO Stephen Matlin. He has offered those with worryingly high results a free second test after three months, to see whether anything has changed. My report also warns, however, that results may reflect temporary illness or ongoing medical treatments – effectively skewing them. And some results on the chart look plain bizarre. One tester, for example, appears to have – at least statistically – a biological age of around 120. Two people aged above 60, together with a clutch of 30-year-olds, have an estimated biological age below zero – presumably because their telomeres are in better shape than might be expected of the average baby. Life Length said this reflected the fact that little research had been done on the telomeres of the very young.
Individual testing, then, is still in nappies. Far more exciting are the possible future advances to come from telomere research, says Blasco. “One is telomerase activation, because of its potential to reverse ageing. And proving which diseases can benefit from telomerase activation, in order for this to be something druggable.”
“Some of the new [research] papers appearing in top journals are to do with telomorase activation,” she says. “That is one aspect. The other is that we are seeing a lot of epidemiological studies showing correlations between telomere length and certain diseases, and which habits are good or bad for telomere length.”
She says the idea that telomeres can be “re-elongated” and, hence, that biological age can be reversed does not open the door to immortality – even if scientists have been able to extend a mouse’s age by up to 40%. “That’s a lot, but nobody has been able to make a mouse that is immortal,” she says.
It does, however, throw up philosophical and ethical dilemmas. The US Food and Drug Administration (FDA), for example, refuses to approve drugs that are simply designed to prevent ageing. “Although I – and many more scientists – believe ageing is the cause of diseases, this is not perceived like that yet by the FDA,” says Blasco. “But what is clear is that there are a number of diseases associated with ageing which are caused because our cells age.”
Activating telomerase to counter that, she says, might help prevent major illnesses and allow drugs to be approved by the FDA. If drugs are found to activate telomerase and prevent, say, Parkinson’s disease, Alzheimer’s disease or some cardiovascular problems then the inevitable result will be not just a healthier life, but also a longer one.
Blackburn agrees that the idea that the new tests can tell you your life length is silly, but she insists that the evidence connecting telomere length and disease risk is becoming clearer.
“We and other groups are seeing clear statistical links between telomere shortness and risk for a variety of diseases that are becoming very common, such as cardiovascular disease, diabetes and certain cancers,” she told the nature.com website in August. “We have also looked at chronic psychological stress, including depression and post-traumatic stress disorder, and more and more we see associations with telomere shortness. There are even links with education — in one study telomere shortness was related to not finishing school. We’re seeing the data unfolding in front of us. A lot of them are not published yet.”
So what has telomere testing done for me? Not a lot, frankly, though I might have reacted differently had I been dangerously off the chart. Nor am I a woman in her 30s, who might like to know how fast the biological clock that may eventually limit fertility is ticking.
I am tempted to repeat the test again, mainly out of a competitive desire to get better, but only if (as on this occasion, when Life Length waived the $500 fee) I can get it for free. Far more interesting, however, has been the glimpse of the future – when telomere testing, and popping pills to repair the tips of our chromosomes, may allow us to live both longer and healthier. I am persuaded, too, that the aim should be to make sure we live our years out in good health. So why all the rushing about? Time, perhaps, to take things more calmly.
guardian.co.uk © Guardian News & Media Limited 2010
Published via the Guardian News Feed plugin for WordPress.
Related Websites 
Can Kim Jong-un be North Korea’s Deng Xiaoping?
As the world waits…to see how North Korea’s Deng Xiaoping handles the his country after the passing of his father, South Korea hopes that there will be better opportunities for cooperation between the two Koreas. For now…a son has lost his father…no matter who you are…a very difficult time in the life of a young man.
http://www.yepod.com/?p=23900
Pass it on,
Dr Anthony
There is little room for nuance in our view of North Korea. State television parades sobbing citizens and soldiers apparently convulsed with grief at the loss of Kim Jong-il. Western commentators dismiss these scenes as propaganda.
Much of this display is certainly ritual, enacted for the camera and for watching comrades and informers. To fail to grieve for the loss of the “dear leader” is a poor career move. But for some the emotions may be real enough: the regime has cultivated in the people an intense gratitude to the Kim family, from the hero-founder Kim Il-sung, whose centenary will be celebrated next year, to his grandson, Kim Jong-un.
Kim Il-sung died in 1994, a time of terrible famine when there was little to be grateful for in North Korea. But refugees interviewed by the American journalist Barbara Demick – men and women who escaped to the south – reported their own intense feelings of bereavement for a leader whom they had been taught to revere as the embodiment of North Korean resistance, nationalism and independence.
Viewed from Beijing, these displays are easier to read: the death of Mao Zedong, whose tyrannical gifts were more than equal to those of the Kim dynasty, sparked similar scenes in China. Like the North Koreans, Chinese had lived under a regime of intense ideological control with limited information about the outside world, and were taught to regard their leader as the embodiment of national resistance to foreign aggression. Mao has never been dethroned as the regime’s founding father, but as Beijing struggles to maintain its own internal stability, the question it asks of its troublesome neighbour is: will North Korea follow the Chinese path to reform?
In China Deng Xiaoping was waiting in the wings, a military and political veteran who triumphed over Mao by outliving him and doggedly undoing his legacy. North Koreans, instead, are expected to transfer their affections to a chubby 28 year-old who was catapulted to four-star general status in September last year. The customary chestful of medals will doubtless follow.
Kim Jong-il was nobody’s political naif, so we must assume that he judged his third son the best available choice. The fact remains that, beyond the cachet of his DNA, Kim Jong-un has no military or political heft. Whether he has any interest in reform is impossible to gauge; whether it would matter if he did seems unlikely – he will depend on the support of military and the party for his power, and any change of course would have to begin there.
Planning for this transition has been under way since Kim Jong-il’s stroke in 2008 with Beijing taking a close interest. China has muted its irritation at North Korea’s repeated provocations and stepped up economic and trade relations as a buffer against any derailment of the succession planning. For now, Beijing hopes it will go smoothly enough to avoid any disturbance in China’s three north-eastern border provinces.
The Chinese army has well-honed contingency plans to intervene in North Korea in the event of a breakdown, but hopes never to be forced to enact them, standing instead as Pyongyang’s guarantor of investment, and of food and energy supplies. Beijing has no desire to cope with a flood of refugees across its nearly 900 miles of border, or to risk the intervention from US-backed South Korea that a collapse in the north could provoke.
The Chinese press has increasingly questioned what China gets out of the relationship with North Korea. For now, though, China has little choice but to pay the bills, while nudging the regime towards the kind of transformational reforms that Deng Xiaoping launched after the death of Mao.
A leadership change offers the regime an opportunity to shape a new narrative, and China’s experience till now shows that economic reform need not threaten authoritarian power. To date, though, Pyongyang has shown only limited enthusiasm for the Chinese model. Without more radical reform, the already enormous economic gap between North Korea and its neighbours will only grow, and keep the country isolated and paranoid.
North Korean dependency on China is already stark: China provides 90% of the investment and accounts for 80% of North Korea’s trade. China is building power plants, roads and transport infrastructure, Chinese businesses have invested in factories in North Korea’s economic development zones, and exports of iron ore and coal to China from North Korea are important earners.
For both Beijing and Pyongyang, this dependency is a mixed blessing. South Korea, Japan and the US may be the bogeymen invoked to frighten North Korean children, but North Korea is also wary of becoming an economic colony of its giant neighbour. North Korea’s main international weapon is blackmail: waving its nuclear capability in the face of the US and threatening China with instability. It works, after a fashion, but it is not a recipe for early reform.
guardian.co.uk © Guardian News & Media Limited 2010
Published via the Guardian News Feed plugin for WordPress.